Trial Profile
Phase III Multi-center, Randomized, Double-masked, Active- and Placebo-controlled Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2017
Price :
$35
*
At a glance
- Drugs Trabodenoson (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms MATrX-1
- Sponsors Inotek Pharmaceuticals
- 11 Apr 2017 According to an Inotek Pharmaceuticals media release, the company has submitted a briefing book to the FDA detailing the results of the completed MATrX-1 trial in order to seek their guidance on its continued development.
- 03 Jan 2017 Top-line results published in a Inotek Pharmaceuticals media release
- 03 Jan 2017 Primary endpoint (Mean Intraocular Pressure) has not been met.